In the race to make the most tolerable obesity drug, there seems to be no clear winner—at least not according to analysts ...

Minovia’s lead product is MNV-201, an autologous hematopoietic stem cell product that is enriched with allogeneic ...

Without providing further context, HHS Secretary Robert F. Kennedy Jr. says that Gavi needs to “start taking vaccine safety ...

Writing in JAMA, four former government officials warn that the Trump administration’s involvement in delaying the approval ...

Susan Monarez, already acting director of the CDC, said during her confirmation hearing that she sees no causal link between ...

Jefferies analysts called the proxy filing, which is a standard disclosure after a merger agreement, “much more intriguing ...

Given today’s available local talent pool, biopharma companies are less likely to turn toward international job candidates, ...

Peter Marks, who headed the FDA’s Center for Biologics Evaluation and Research before being forced to resign in March, said the agency’s new risk-based COVID-19 vaccine framework contradicts the ...

Leading companies spent $1.4 billion upfront on licensing deals and embarked on vast R&D programs. Clinical setbacks mean ...

On day one of the highly anticipated first meeting of the CDC's newly formed vaccine advisory committee, members debated the ...

Are long R&D cycles, overwhelming literature reviews, or patent bottlenecks slowing your path to innovation? In the ...

Gilead is betting up to $750 million on Kymera’s anti-CDK2 molecular glue for solid tumors, while Sanofi elected to move ...